Truist raised the firm’s price target on CVS Health (CVS) to $84 from $82 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Proposal to cut Medicaid spending aims for GOP middle ground, WSJ says
- Many patients soon to be forced to switch obesity drug, NYT says
- CVS, Oracle, Caterpillar, RTX, AGNC: Insider Moves Unveiled
- Palantir Stock (PLTR) Dethroned as S&P 500’s Top Performer in 2025
- Glenviw issues statement on CVS Health